Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)

XABIER GARCÍA-ALBÉNIZ,† XABIER GARCÍA-ALBÉNIZ,† VICENTE ALONSO,‡ PILAR ESCUDERO,‡‡ MIGUEL MÉNDEZ,‡ JAVIER GALLEGOS,‡ JOSE RAMÓN RODRÍGUEZ,§ ANTONIA SALUS,ª JULEN FERNÁNDEZ-PLANA,ª HERMINI MANZANO,ª MONTSERRAT ZANUI,ª ESTER FALCÓ,ª JAIME FELIU,ª MIRIAM CUATRECASAS,ª JOAN MAUREL,ª† CARLOS FERNÁNDEZ-MARTOS,ª URIEL BOHN,ª CARMEN ALONSO,ª VERÓNICA CALDERERO,ª FEDERICO ROJO,ª MIRIAM CUATRECASAS,ª JOAN MAUREL,ª†

ªDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; ‡RTI Health Solutions, Barcelona, Spain; ‡§Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain; ‡§Medical Oncology Service, Hospital Universitario Lozano Blesa, Zaragoza, Spain; ‡§Medical Oncology Service, Hospital de Móstoles, Móstoles, Spain; ‡§Medical Oncology Service, Hospital General Universitario de Elche, Elche, Spain; ‡§Medical Oncology Service, Hospital Infantia Cristina, Badajoz, Spain; ‡§Medical Oncology Service, Hospital Universitari Arnau de Vilanova, Lleida, Spain; ‡§Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ‡§Medical Oncology Service, Hospital Son Espases, Palma, Spain; ‡§Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain; ‡§Medical Oncology Service, Hospital Universitario Lozano Blesa, Zaragoza, Spain; ‡§Medical Oncology Service, Hospital de Móstoles, Móstoles, Spain; ‡§Medical Oncology Service, Hospital General Universitario de Elche, Elche, Spain; ‡§Medical Oncology Service, Hospital Infantia Cristina, Badajoz, Spain; ‡§Medical Oncology Service, Hospital Universitari Arnau de Vilanova, Lleida, Spain; ‡§Medical Oncology Service, Hospital Mútua de Terrassa, Spain; ‡§Medical Oncology Service, Hospital Son Espases, Palma, Spain; ‡§Medical Oncology Service, Hospital de Mataró, Mataró, Spain; ‡§Medical Oncology Service, Hospital Son Llàtzer, Palma, Spain; ‡§Medical Oncology Department, CIBERONC, Hospital Universitario La Paz, Madrid, Spain; ‡§Medical Oncology Service, Hospital de Sagunto, Sagunto, Spain; ‡§Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain; ‡§Medical Oncology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; ‡§Medical Oncology Department, Hospital de León, Spain; ‡§Medical Oncology Department, Hospital General de Barbastro, Spain; ‡§Pathology Service, Hospital Fundación Jiménez Díaz, Madrid, Spain; ‡§Department of Pathology, Hospital Clinic, Banc de tumors Clínic-IDIBAPS; CIBEREHD and University of Barcelona, Spain; ‡§Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain

†Contributed equally.

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Colorectal cancer • Biomarkers • Cetuximab • Clinical score

ABSTRACT

Background. RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively assessed to predict anti-EGFR resistance.

Materials and Methods. We designed a multicenter prospective trial (NCT01276379) to evaluate whether the biomarkers BRAF mutation, PIK3CA/PTEN mutation, and DP phenotype could improve the prediction for 12-month progression-free survival (PFS) in mCRC treated with standard chemotherapy plus biweekly cetuximab. The planned sample size was 170 RAS WT patients to detect a 20% difference in 12-month PFS based on the analysis of clinical and selected biomarkers (α = .05, β = .2). The discriminatory capacity of the biomarkers was evaluated using receiver operating characteristic curves.

Results. We included 181 RAS WT patients. The biomarker distribution was as follows: BRAF mutant, 20 patients (11%); PIK3CA mutated/PTEN loss, 98 patients (58%); DP, 23 patients (12.7%). The clinical variables in the clinical score were progression status >0, left-sided tumor, and resectable liver metastasis as the only metastatic site. The area under the curve (AUC) of the score containing the clinical variables was 0.67 (95% confidence interval [CI], 0.60–0.75). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58–0.73, p = .09). The AUC of the score with clinical variables and BRAF mutational status was 0.68 (0.61–0.75, p = .37). The AUC of the score with clinical variables and PI3KCA mutation/PTEN status was 0.69 (0.61–0.76, p = .32). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58–0.73, p = .09).

Conclusion. The addition of BRAF, PIK3CA/PTEN, and DP to a clinical score does not improve the discrimination of 12-month PFS. The Oncologist 2019;24:e1115–e1122

Correspondence: Xabier García-Albéniz, M.D., Ph.D., Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, Massachusetts 02115, USA. Telephone: 617-432-6921; e-mail: xabi@post.harvard.edu. Received October 26, 2018; accepted for publication May 15, 2019; published Online First on June 24, 2019. http://dx.doi.org/10.1634/theoncologist.2018-0728

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Implications for Practice: This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers.

**INTRODUCTION**

Colorectal cancer (CRC) is the third most frequent cause of cancer-related death in Western countries, accounting for 10% of all cancer incidence and mortality. RAS mutations are found in 50% of metastatic colorectal cancer (mCRC). BRAF mutation is found in 10% of patients with mCRC and confers poor prognosis [1]. Treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab) has shown efficacy in patients with KRAS wild-type (WT) mCRC in retrospective analyses [2, 3] and all-RAS WT both in retrospective analysis and in prospective randomized clinical trials (RCT) of first-line therapy (cetuximab and panitumumab plus chemotherapy over chemotherapy alone) [4, 5].

The evidence of other potential biomarkers to predict anti-EGFR intrinsic resistance, such as BRAF mutation, PIK3CA mutation, or PTEN loss of expression, needs further validation because available data come mainly from retrospective cohorts that constitute the lower level of evidence in biomarker studies [6–13]. Our group identified in a retrospective analysis that the coexpression of matrix metalloproteinase-7 (MMP7) and phosphorylated insulin growth factor receptor (p-IGF-R; double positive [DP] phenotype) is associated with worse prognosis in patients with WT KRAS mCRC treated with anti-EGFR [14]. BRAF, PIK3CA, and PTEN have been evaluated in RCTs, the gold standard to validate prognostic biomarkers [15], to predict the efficacy of panitumumab [16, 17] or cetuximab [17, 18], and the results were contradictory.

The objective of this prospective study was to assess whether the biomarkers BRAF, DP, and PIK3CA/PTEN improve the prediction of 12-month progression-free survival (PFS) over the use of only clinical variables in patients with mCRC RAS WT treated with standard chemotherapy, plus biweekly cetuximab, as first-line therapy.

**MATERIALS AND METHODS**

**Patients, Treatment, and Follow-Up**

The study was conceived as a prospective biomarker cohort (ClinicalTrials.gov identifier: NCT01276379). Patients were eligible if they were ≥18 years, with histologically confirmed WT RAS metastatic adenocarcinoma of the colon or rectum, presence of at least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, an Eastern Cooperative Oncology Group Performance Status (PS) of 0–1, an estimated life expectancy greater than 3 months, and adequate hepatic (serum bilirubin ≤1.5 × upper limit of normal [ULN], alanine aminotransferase, and aspartate amino transferase ≤2.5 × ULN or ≤5 × ULN in the presence of liver metastases), renal (serum creatinine ≤1.5 × ULN), and bone marrow (neutrophils ≥1.5 × 10^9 cells per L, platelets ≥100 × 10^9 per L, and hemoglobin ≥9 g/dL) functions. Patients were ineligible if they were pregnant or previous recipients of anti-EGFR or chemotherapy (with the exception of adjuvant therapy more than 6 months prior) or if they had undergone surgery for metastatic disease before study entry. Patients were also excluded if they had clinically relevant coronary heart disease or myocardial infarction within the past 12 months; were at risk of uncontrolled arrhythmia, known or suspected brain metastases, or acute or subacute intestinal obstruction; or had a history of chronic inflammatory disease or chronic diarrhea, a pre-existing dihydroprymidine dehydrogenase deficiency, a pre-existing glucuronidation defect (Gilbert syndrome), or a history of secondary malignancy within the past 5 years, except for basal cancer or carcinoma in situ of the cervix if treated with curative intent.

Patients received biweekly cetuximab (500 mg/m^2 every 2 weeks) with either modified mFOLFOX6 or FOLFIRI. mFOLFOX6 consists of oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2, fluorouracil 400 mg/m^2 in bolus, and fluorouracil 2,400 mg/m^2 in 46-hour continuous infusion. FOLFIRI consists of irinotecan 180 mg/m^2, leucovorin 400 mg/m^2, fluorouracil 400 mg/m^2 in bolus, and fluorouracil 2,400 mg/m^2 in 46-hour continuous infusion. Chemotherapy choice was at the discretion of the treating physician. Treatment was continued until disease progression, unacceptable toxicity, patient refusal, physician decision, or 12 cycles of mFOLFOX6 or FOLFIRI (cetuximab could be continued beyond 12 cycles in the absence of progression). Dose modifications of chemotherapy and cetuximab were permitted and specified in the protocol.

After an initial baseline assessment within 28 days of the start of study treatment, investigators assessed tumor response by computed tomography scan and/or magnetic resonance imaging every 12 ± 2 weeks of treatment and at the end of treatment. Subsequent follow-up was done every 3 months. Adverse events were recorded from enrollment to the end of the final study visit and were classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The study was approved by institutional review boards of participating centers.

**RAS/BRAF and PIK3CA Mutational Analysis**

Mutational analysis of genomic DNA of KRAS (exon 2) was performed by direct sequencing at each center. Extended RAS mutational analysis (including KRAS/NRAS exons 2, 3, and 4) started on October 2015 in the POSIBA trial after protocol amendments. Pyrosequencing of KRAS and NRAS codons 12, 13, 59, 61, 117, and 146 was performed using Therascreen KRAS and NRAS Pyro Kits (Qiagen, Hilden, Germany), according to manufacturer’s instructions. DNA...
from two 5-μm tissue sections was isolated using QIAamp DNA FFPE Tissue Kit (Qiagen). Then, 10 ng/μl DNA templates were amplified in a SimpliAmp thermal cycler (Applied Biosystems, Foster City, CA) targeting codons of interest. Amplicons were then immobilized on Streptavidin Sepharose High Performance beads (GE Healthcare, Little Chalfont, U.K.). The thus obtained single-stranded DNA was prepared with the corresponding sequencing primers to DNA annealing. Further pyrosequencing run and analysis were carried out on the Pyromark Q24 system along with the software version 2.0 KRAS and NRAS plug-in reports (Qiagen). Mutation thresholds were identified in relation to the manufacturer’s limit of detection for the specific mutations. Both wild-type control DNA and nontemplate control were included in every run for comparison and background levels screening.

The BRAF V600E mutation (exon 15) was genotyped by allelic discrimination in genomic DNA using TaqMan technology (Applied Biosystems, Foster City, CA).

Activating mutations in PIK3CA tend to cluster in hot-spots, 80% of which are accounted for by oncogenic substitution in exon 20 (H1047R) and exon 9 (E542K and E545K), which encode portions of the helical and kinase domains. Known PIK3CA mutations in these exons were evaluated using the Sequenom MALDI TOF MassARRAY system.

**Figure 1.** Patient flowchart.

PTEN, p-IGF-1R, and MMP7 Immunohistochemistry Analysis

We used H&E staining to evaluate the presence and classification of the tumor specimens. Consecutive 3-μm-thick sections were used for immunohistochemistry (IHC). Paraffin removal and heat incubation in citrate (pH = 6.0) were carried out for antigen retrieval. The primary p-IGF-1R antibody (anti-pY1316, provided by Dr. Rubini) was used at 1:100 dilution [19]. The most common pattern of expression was dot-like perinuclear or Golgi pattern. Membrane location was unfrequent. Nuclear pattern was seen in 15%–20% of cases, and the percentage of positive nuclei was used to score the nuclear pattern of staining. MMP-7 (Monoclonal Mouse IgG2b Clone no. 11433; R&D Systems, Minneapolis, MN) was used at 1:1,500 dilution, and the pattern of staining was cytoplasmatic. Detection was performed using the Dako EnVision K4011 (Agilent, Santa Clara, CA). IHC evaluation was conducted after patient inclusion. Coexpression of pIGF-1R and MMP-7 (termed DP phenotype) was defined as moderate = 2 or strong = 3 intensity and >70% expression for both MMP-7 and pIGF-1R. Normal colon mucosa expression was low for both antibodies. PTEN protein expression on tissue sections was evaluated using the mouse monoclonal anti-PTEN clone 6H2.1 (Dako; Agilent, Copenhagen, Denmark) [20], and antigen-antibody reaction was detected using Flex+ (Dako; Agilent) and developed with DAB. Quantification of PTEN expression was executed by a senior pathologist (F.R.). pIGF-1R, MMP-7, and PTEN immunostains were scored semi-quantitatively using the previously described immunoreactive score (IRS) [20]: IRS = staining intensity (SI) × percentage of positive cells (PP). SI was defined as 0 = absence of staining; 1 = weak; 2 = moderate; and 3 = strong. PP was defined as 0 < 1%; 1 = 1%–10%; 2 = 11%–50%; 3 = 51%–80%; and 4 > 80% positive cells. Ten visual fields from different areas of each tumor were evaluated for IRS. Slides without primary antibody were included as negative controls and normal epithelium of stromal cells known to express PTEN, MMP7, and pIGF-1R were used as positive controls. IRS of 0 corresponds to PTEN-lost tumors with nondetectable level of PTEN staining, and IRS of 12 represents full PTEN expression in normal individuals. PTEN loss was defined as IRS of 3 or less.

**Statistical Analysis**

To quantify whether the biomarkers BRAF, DP, and PIK3CA-PTEN do improve the prediction of 12-month PFS over the use of only clinical variables in the study population, we compared the area under the curve (AUC) of a receiver operating characteristic (ROC) curve using scores composed by clinical variables with the AUC of scores with the clinical variables plus each of the biomarkers. The clinical variables were age, sex, performance status, primary tumor side (transverse and ascending colon were considered right side), number of organs affected, type of organ, surgery of primary tumor, liver-limited resectable disease (less than three nodes <5 cm), hemoglobin, leucocytes, platelets, alkaline phosphatase, and lactate dehydrogenase levels. To build the clinical score, we (a) ran univariate analyses for each variable and PFS using Cox regression models. (b) Those variables with a p value ≤0.15 in the univariate analyses were included in a multivariate Cox model. (c) Their coefficients were added to construct the score [21]. The biomarker scores were constructed by adding each biomarker to the model of the step 2 and repeating step 3. The discriminatory capacity of each score was quantified by the AUC of a ROC curve.

Primary endpoint was progression-free survival at 12 months. PFS was defined as the time from inclusion to documented progression, death (both considered events), last follow-up, or the administrative end of follow-up (both
considered censoring reasons), whichever happened first.
Sample size was computed to detect an increase of 20% in 12-month PFS (i.e., from 40% in the group with worse prognostic biomarkers to 60% in those with better prognostic biomarkers) under the following assumptions: two-sided $\alpha$ error of 5%, $\beta$ error of 20%, percentage of patients classified in the worse prognostic biomarker group of 40%, a recruitment of 8 patients per month, a follow-up of 28 months, and 10% losses. Under these assumptions, 170 patients were required. Kaplan-Meier curves were used to plot PFS by score.
Table 2. Univariate and multivariate models for the scores

| Variables                          | Univariate, HR (95% CI) | p value | Multivariate clinical, HR (95% CI) | Clinical score weight | Multivariate BRAF, HR (95% CI) | BRAF score weight | Multivariate PI3K/PTEN, HR (95% CI) | PI3K/PTEN score weight | Multivariate DP, HR (95% CI) | DP score weight |
|-----------------------------------|-------------------------|---------|-----------------------------------|-----------------------|-------------------------------|--------------------|-----------------------------------|--------------------------|------------------------|---------------------|
| Female                            | 0.97 (0.69–1.36)        | .87     |                                   |                       |                               |                    |                                   |                          |                        |                     |
| PS >0                             | 2.02 (1.46–2.79)        | <.0001  | 1.80 (1.29–2.51)                  | 0.6                   | 1.73 (1.24–2.42)              | 0.5                | 1.72 (1.22–2.41)                  | 0.5                      | 1.78 (1.27–2.49)       | 0.6                |
| Age >65 y                         | 1.18 (0.87–1.61)        | .30     |                                   |                       |                               |                    |                                   |                          |                        |                     |
| FOLFIIRI + cetuximab              | 1.62 (1.19–2.22)        | .0024   | 1.48 (1.08–2.03)                  | NA                    | 1.44 (1.05–1.98)              | NA                 | 1.43 (1.04–1.96)                  | NA                       | 1.47 (1.07–2.02)       | NA                 |
| Surgery primary                   | 1.02 (0.74–1.39)        | .92     |                                   |                       |                               |                    |                                   |                          |                        |                     |
| Left sided                        | 0.55 (0.39–0.78)        | .0008   | 0.59 (0.41–0.84)                  | −0.5                  | 0.59 (0.42–0.84)              | −0.5               | 0.58 (0.41–0.83)                  | −0.5                     | 0.58 (0.41–0.83)       | −0.5               |
| Log CEA                           | 1.03 (0.96–1.10)        | .40     |                                   |                       |                               |                    |                                   |                          |                        |                     |
| LDH >450                          | 1.05 (0.75–1.47)        | .40     |                                   |                       |                               |                    |                                   |                          |                        |                     |
| Only resectable liver mets        | 0.64 (0.34–1.18)        | .15     | 0.70 (0.37–1.32)                  | −0.4                  | 0.71 (0.38–1.32)              | −0.3               | 0.67 (0.34–1.31)                  | −0.4                     | 0.70 (0.37–1.31)       | −0.4               |
| Mutant BRAF                       | 2.33 (1.44–3.79)        | .0006   | 2.10 (1.23–3.29)                  | 0.7                   |                               |                    |                                   |                          |                        |                     |
| PI3K mutant or PTEN s3            | 0.83 (0.61–1.13)        | .24     | 0.81 (0.59–1.11)                  | −0.2                  |                               |                    |                                   |                          |                        |                     |
| DP                                | 1.24 (0.79–1.94)        | .36     | 1.10 (0.68–1.76)                  | 0.1                   |                               |                    |                                   |                          |                        |                     |

*Models are adjusted for this variable, but it is not used to build the scores because it is not an intrinsic characteristic of the patients.

Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; DP, double positive; HR, hazard ratio; LDH, lactate dehydrogenase level; NA, not applicable; PS, performance status.

**RESULTS**

We screened 212 patients from 28 Spanish Centers between July 2011 and May 2015, 181 of whom were eligible. PI3KCA mutation/PTEN loss could be evaluated in 167 patients, and BRAF mutational status and DP expression could be evaluated in all of them. In the 212 patients included in the study, 115 patients who started treatment with mFOLFOX6 received a median number of 16.1 cycles, and the 97 patients who started treatment with FOLFIIRI received a median number of 12.6 cycles. A total of 71 of the 115 (61.7%) patients treated with mFOLFOX6 received 12 or more cycles compared with 52 of 97 patients (53.6%) with FOLFIIRI. See Figure 1.

Patients were followed for a median of 28.6 months (95% confidence interval [CI], 22.9–34.3), and 163 (90%) progressed during the follow-up, 103 (57%) during the first year. Baseline characteristics by biomarker are shown in Table 1. Patients with mutant BRAF tumors (n = 20, 11%) were older and showed a higher incidence of right-sided tumors, worse PS, and lymph node and peritoneal metastases. Patients with PI3KCA mutation/PTEN loss (n = 98, 58%) showed no relevant differences in baseline characteristics compared with those without it. Patients with DP phenotype (n = 23, 12.7%) were older and had worse PS.

Median PFS was 11.4 months in patients with WT BRAF tumors and 5.9 months in patients with mutant BRAF tumors (p = .004). There were no differences on prognosis according to PI3KCA mutations (p = .43) and PTEN loss (p = .25), analyzed separately. PI3KCA/PTEN pathway and DP phenotype did not discriminate PFR (p = NS). Baseline clinical variables with good prognosis in a multivariable model were PS = 0, left-sided tumor, and resectable liver metastases (i.e., liver-only metastases [less than three nodules <5cm]).

The clinical variables with p values ≤.15, thus chosen to build the clinical score, were PS >0, left-sided tumor, and resectable liver metastasis as the only metastatic site (Table 2). Chemotherapy regimen was significant in the univariate analysis. It was excluded from the scores because it is not an intrinsic characteristic of the patient, but all the score models were adjusted for it. Table 2 contains the multivariate models built with each of the biomarkers and the clinical variables identified in the multivariate analysis, as well as the weight assigned to build each score. The AUC of the score containing the clinical variables was 0.67 (95% CI, 0.60–0.75). The AUC of the score with clinical variables and BRAF mutational status was 0.68 (0.61–0.75, p = .37). The AUC of the score with clinical variables and PI3KCA mutation/PTEN status was 0.69 (0.61–0.76, p = .32). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58–0.73, p = .09; Fig. 2). PFS under each score classification (dichotomized by the most discriminative cut-point) was
equivalent under the four scores (Fig. 3). The combination of the three biomarkers and the clinical variables did not improve the AUC (0.69; 95% CI, 0.62–0.77).

**DISCUSSION**

We present data from a prospective biomarker study to assess the prognostic value of selected biomarkers in patients with RAS WT mCRC treated in first line with a combination of standard chemotherapy plus biweekly cetuximab. We could not find proof that adding biomarker determination (BRAF, PIK3CA/PTEN, DP) to the use of only clinical variables improves patient classification into those who will progress by the first year after diagnosis of metastatic disease and those who will not.

Several studies that have analyzed BRAF and PIK3CA/PTEN are either retrospective cohorts or retrospective biomarker analysis on RCTs (summarized in Table 3). To our knowledge, our study is the first to prospectively analyze the prognostic value of these biomarkers using an a priori-defined hypothesis and an upfront sample size.

In a retrospective analysis of refractory patients, our group found a negative prognostic value of DP phenotype for patients treated with irinotecan and cetuximab; those patients represented 25% of the sample in refractory patients, whereas in first line, only 12.7% of the patients presented DP

© 2019 The Authors.
*The Oncologist* published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
phenotype. Nevertheless, the differences between frequencies could be explained as a result of the induction of a mesenchymal phenotype in pretreated patients [22]. Activating mutations in PIK3CA and PTEN loss of expression are in the range (29%–72%) of previous published studies [6–13].

Neither DP nor PIK3CA/PTEN showed independent association with PFS in our study. Our results confirm the prognostic value of BRAF mutation in this setting [1]. However, despite the significance in multivariant analysis, it did not improve the discrimination of the clinical score, probably because of the small number of BRAF-mutant patients (11%) and collinearity with other clinical variables. Biomarkers that could actually improve the classification of these patients may be mutations other than BRAF and PIK3CA [23] or non-mutational driver pathways related to anti-EGFR resistance, located mainly in primary right-side tumors [24].

We believe that our approach has several strengths compared with enriched randomized designs [25]. First, we do not preassumption that the proposed biomarkers really are drivers for targeted agent prediction and therefore allow for better evaluation of multiple biomarkers. Second, a reduced number of patients is needed to avoid patient loss because of stratification procedures. Third, all clinical variables that potentially could influence PFS are included, minimizing bias and enforcing the truly independent value of the biomarkers. The only prospective biomarker study in mCRC that uses an enriched design has recently evaluated the efficacy of AZD8931 (an EGFR, HER2, and HER3 inhibitor) in patients with quadruple WT mCRC (FOCUS4-D) [26]. As an example, in this study, only 32 out of 132 patients (24% of potentially eligible quadruple WT patients) were finally randomized. Our study highlights the importance of clinical variables such as Eastern Cooperative Oncology Group PS, liver resectable disease, and sidedness [27]. Despite these strengths, we recognize several limitations: radiological assessment was not centralized, patients were treated with two different chemotherapy schedules, and PTEN score and DP phenotype interpretation can be subjective.

**CONCLUSION**

Our study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation, in and of itself, and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. Nevertheless, the use of a triple blockage strategy (BRAF/MEK/EGFR or BRAF/PIK3CA/EGFR) in BRAF-mutant patients showed a rather modest activity (20% response rate and 4-months PFS) [28, 29]. These results support the notion that additional pathways of resistance should be evaluated in BRAF-mutant patients.

**ACKNOWLEDGMENTS**

This study was financially supported by Merck, S.L.U. (Spain), an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this article, and the views and opinions described in the publication reflect solely those of the authors. This
article was previously presented at the European Society for Medical Oncology, October 19–23, 2018, in Munich, Germany.

Author Contributions

Conception/design: Xavier García-Albéniz, Vicente Alonso, Pilar Escudero, Miguel Méndez, Javier Gallego, Jose Ramon Rodríguez, Antonia Salud, Julen Fernández-Plana, Hermini Manzano, Montserrat Zanui, Ester Falcó, Jaime Feliu, Mireia Gil, Carlos Fernández-Martos, Uriel Bohn, Carmen Alonso, Verónica Calderero, Federico Rojo, Miriam Cuatrecasas, Joan Maurel

Provision of study material or patients: Xavier García-Albéniz, Vicente Alonso, Pilar Escudero, Miguel Méndez, Javier Gallego, Jose Ramon Rodríguez, Antonia Salud, Julen Fernández-Plana, Hermini Manzano, Montserrat Zanui, Ester Falcó, Jaime Feliu, Mireia Gil, Carlos Fernández-Martos, Uriel Bohn, Carmen Alonso, Verónica Calderero, Federico Rojo, Miriam Cuatrecasas, Joan Maurel

Collection and/or assembly of data: Xavier García-Albéniz, Vicente Alonso, Pilar Escudero, Miguel Méndez, Javier Gallego, Jose Ramon Rodríguez, Antonia Salud, Julen Fernández-Plana, Hermini Manzano, Montserrat Zanui, Ester Falcó, Jaime Feliu, Mireia Gil, Carlos Fernández-Martos, Uriel Bohn, Carmen Alonso, Verónica Calderero, Federico Rojo, Miriam Cuatrecasas, Joan Maurel

REFERENCES

1. Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322–5330.

2. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2009;66:3953–3992.

3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643–2648.

4. Douillard JY, Oliner KS, Siena S et al. Panitumumab–FOLOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023–1034.

5. Van Cutsem E, Lenz HJ, Khoan CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692–700.

6. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–57012.

7. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139–1145.

8. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851–1857.

9. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924–5930.

10. Perrone F, Lampis A, Orsenigo M et al. PIK3CA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84–90.

11. Prenen H, De Schutter J, Jacobs B, De Rook W, Biezens M, Baes C, Lambrechts D, Van Cutsem E, Teijpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184–3188.

12. De Rook W, Baes C, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753–762.

13. Tian S, Simon I, Moreno V et al. A combined oncogenic pathway signature of BRAF, KRAS and PIK3CA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013;62:540–549.

14. Hördler C, Gallego R, García-Albéniz X et al. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. Cancer Biol Ther 2011;11:177–183.

15. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027–4034.

16. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil–capecitabine–irinotecan resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomized trial. Lancet Oncol 2013;14:749–759.

17. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902–1912.

18. Karapetis CS, Jonker D, Daneshmand M et al. NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer–results from NCIC CTG/AGITG CO.17. Cancer Clin Res 2014;20:744–753.

19. Rubini M, D’Ambrosio C, Carturan S et al. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers. Exp Cell Res 1999;251:22–32.

20. Nagata Y, Lin KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117–127.

21. Meigs JB, Shadrer P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208–2219.

22. Sanchez-Lopez E, Flashner-Abramson E, Shalapour S et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor–insulin receptor substrate and STAT3 signaling. Oncogene 2016;35:2634–2644.

23. Cremolini C, Morano F, Moretto R et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibody bodies: THE PRESSING case-control study. Ann Oncol 2017;28:3009–3014.

24. Trinh A, Trumpi K, De Sousa E Melo F et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin Cancer Res 2017;23:387–398.

25. Renfro LA, Mallick H, An MW et al. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev 2016;43:74–82.

26. Adams R, Brown E, Brown L et al. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUL4-D): A phase 2-3 randomised trial. Lancet Gastroenterol Hepatol 2018;3:162–171.

27. Arnold D, Lueza B, Douillard JY et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28:1713–1729.

28. van Geel RMJ, Tabernero J, Elle E et al. A Phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic Braf-mutant colorectal cancer. Cancer Discov 2017;7:610–619.

29. Corcoran RB, André T, Attrey CE et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF mutant colorectal cancer. Cancer Discov 2018;8:428–443.